AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|
12.7 C
New York
Thursday, November 12, 2026

Tag: products

newsFORsourcecompanycontentinformationreleases1IT

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub (“HTH”) Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute (“ARMI”) and its BioFabUSA initiative.

ENGWE Will Present Its New Product Line MapFour at Eurobike with Upgraded Models

FRANKFURT, Germany, June 20, 2025 /PRNewswire/ -- ENGWE, a global leader in electric mobility, will showcase its latest innovations at Eurobike 2025, held in Frankfurt...

BC Tech Pioneers Quality Upgrade in PV Industry

SHANGHAI, June 20, 2025 /PRNewswire/ -- During the recent 2025 SNEC exhibition in Shanghai, LONGi, a global leader in PV technology innovation, signed a strategic...

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Analyzing Annuity Costs: A Detailed Breakdown for Strategic Financial Planning

Annuities, while potentially beneficial under certain circumstances, require careful scrutiny due to their associated costs. The primary concern is the substantial fees that can...

Fed Maintains Interest Rates—Evaluate Implications for Credit Cards, Auto Loans, Mortgages

The Federal Reserve's decision to maintain the current interest rate reflects a strategic pause amid an evolving economic landscape. Given President Trump's calls for...

SBI Life crowdsources future-facing AI solutions from India’s Next-Gen Talent pool at the 2025 Hack-AI-Thon finale

The initiative underscored SBI Life's focus on innovation, young talent, and building future-ready insurance solutions MUMBAI, India, June 20, 2025 /PRNewswire/ -- SBI Life Insurance,...

Prosthetic Eye Market Innovation—Evaluating Investment in Specialized Medical Devices

Christina Leitzel, renowned in the niche field of ocular prosthetics, approaches her craft with precision akin to that of an art forger. This meticulous...

Chinese Firms Eye Brazil—Because Who Needs Stability Anyway?

Amid the relentless cacophony of trade wars and collapsing markets, Chinese consumer brands, with a touch of desperation and a sprinkle of audacity, have...

Cochlear celebrates 30 Years in China and the launch of the world’s first and only smart hearing implant system

The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+This year marks the 30-year anniversary since...

OMS Energy Technologies Inc. Issues Post-IPO Operational Update Featuring Customer Growth, Expansion Initiatives and R&D and Safety Achievements

SINGAPORE, June 19, 2025 (GLOBE NEWSWIRE) -- OMS Energy Technologies Inc. (“OMS” or the “Company”) (Nasdaq: OMSE), a growth-oriented manufacturer of surface wellhead systems (“SWS”) and oil country tubular goods (“OCTG”) for the oil and gas industry, today provided a business update outlining its recent accomplishments as the Company prepares for its inaugural earnings call following its successful Nasdaq listing in May 2025.

BingX New Dual Investment Offering Sees $1M in User Participation

PANAMA CITY, June 20, 2025 /PRNewswire/ -- BingX, a leading cryptocurrency exchange and Web3 AI company, has officially launched its Dual Investment product, aimed...

HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support

HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care 
HealthRX enhances online platform to offer doctor-prescribed GLP-1 medications like Ozempic® and Zepbound® for adults seeking virtual weight loss support, prescription access, and 24/7 telehealth care

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProducts

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers